Amylin controls nutrient fluxes by reducing food intake, slowing gastric emptying and reducing postprandial glucagon secretion via a direct effect on the area postrema (AP). In the AP, amylin seems to modulate the anorectic signal elicited by cholecystokinin (CCK). Amylin's excitatory action on AP neurons and its anorectic effect may depend on diet composition because rats fed protein as exclusive energy source showed a blunted response to amylin. In addition to a role in satiation ("episodic signal"), recent studies suggest that amylin may also play a role as an adiposity ("tonic") signal. Similar to leptin or insulin, an elevated brain level of amylin resulted in lower body weight gain than in controls. This may also in part be due to an increase in energy expenditure. Overall, amylin may be an interesting target as a body weight lowering drug. Recent studies provided evidence that amylin, especially when combined with insulin, leptin or PYY has long-term effects on food intake and body weight in humans.
Introduction
Amylin is synthesized by the pancreatic B-cells and is co-secreted with insulin. In conjunction with insulin, amylin controls nutrient flux and the postprandial glucose concentration. E.g., amylin inhibits gastric acid secretion, gastric emptying, pancreatic glucagon secretion, digestive enzyme secretion, and eating. The best investigated amylin function is its role as a hormonal control of meal ending satiation. Acute peripheral amylin reduces meal size. The effect is behaviorally specific. Unlike cholecystokinin (CCK), amylin may also act as an adiposity signal, such as leptin and insulin. Amylin's basal blood concentration is correlated with the total amount of body fat.
This information may be used as a feedback signal controlling energy homeostasis, i.e., food intake and energy expenditure.
Physiological relevance of amylin as satiation signal
Amylin meets most of the criteria for a physiological satiation signal in rats (Table 1 ; Lutz et al., 1995; Geary, 2004) . First, food intake rapidly increases plasma amylin concentration within few minutes. 6 The magnitude of this increase is correlated with the amount eaten (Butler et al., 1990; Lutz et al., 1997) . Second, all components of functional amylin receptors which consist of the calcitonin receptor (CT-R) as a core receptor and receptor-activity modifying proteins (RAMP 1 or RAMP 3), are present in the area postrema (AP) where amylin appears to act to inhibit eating (reviewed in Lutz, 2005; Lutz, 2006) . Third, low doses of exogenous amylin that yield plasma amylin levels only about two times higher than those measured postprandially, significantly inhibit eating (Pieber et al., 1994; Arnelo et al., 1998; Reidelberger et al., 2004) . Forth, as to hormone or receptor removal and replacement, indirect evidence is provided by the amylin knockout mouse, which shows the expected phenotype of overeating and increased adiposity (Devine and Young, 1998; Lutz, 2005) . Finally, peripheral or central amylin antagonists produce an effect opposite to that of amylin. E.g., when AC187 is administered into the AP, it blocks the anorectic effect of intraperitoneally injected amylin and, when administered alone, stimulates eating by an increase in meal size (Mollet et al., 2004) .
Mechanisms of amylin action.
The AP lacks a functional blood brain barrier. Neurons in the AP with amylin receptors seem to play an essential role in peripheral amylin action. Amylin binding sites occur in high densities in the AP (Sexton et al., 1994) and amylin-sensitive AP neurons carry the CT-R . Both RAMP1 and RAMP3 mRNA are also present in the mouse AP (Oliver et al., 2001; Ueda et al., 2001) , and amylin-induced Fos mRNA and RAMP3 mRNA expression colocalize in rat AP cells (Barth et al., 2004) . Further, the anorectic actions of both acute and chronic peripheral amylin are eliminated in rats with lesions in the AP/NTS region (Lutz et al., 1998b; Lutz et al., 2001a) . Lesions of vagal and non-vagal visceral afferents left amylin's effect unaltered (Morley et al., 1994; Lutz et al., 1998a) .
Endogenous amylin released during meals also appears to act via AP amylin receptors because direct infusion of the amylin receptor antagonist AC187 into the AP increased food intake (Mollet et al., 2004) . Further, peripheral exogenous amylin and endogenous amylin triggered by post-deprivation refeeding increased neuronal activation in the AP, characterized by the expression of Fos protein (Riediger et al., , 2002 . Finally, in vitro studies showed that direct application of amylin onto AP neurons in brain slice preparations dose dependently increased the neuronal firing rate (Riediger et al., , 2002 .
Whether more rostral amylin receptors also contribute to the anorectic action of amylin, remains to be established. Amylin infusion into the third brain ventricle (i3vt) produces a potent and long-lasting reduction in feeding, and i3vt infusion of AC187 increases food intake and body weight in rats (Rushing et al., 2000a ).
Secondary to AP activation, peripheral amylin also elicits a positive Fos response in brain sites rostral to the AP, including the nucleus of the solitary tract (NTS), the lateral parabrachial nucleus (lPBN), and the central nucleus of the amygdala (CeNA) (Rowland et al., 1997; Rowland and Richmond, 1999; Riediger et al., 2004) . None of these areas is activated by amylin in AP-lesioned animals. The AP, NTS, and the lPBN are necessary to convey amylin's anorectic signal to higher brain structures (Lutz et al., 1998b; Riediger et al., 2004; Becskei et al., 2007) .
Interestingly, the same areas also seem to process other anorectic signals, such as CCK. However, at least partially different neuronal networks seem to mediate the effects of different peptides. CCK, but not amylin satiation involves the central serotoninergic system, while the dopaminergic and histaminergic systems contribute to amylin signaling (Lutz et al., 1996; Lutz et al., 2001b; Mollet et al., 2001 ).
The amylin-mediated Fos response in the AP is modulated by nutrients
The AP as the necessary brain site to mediate peripheral amylin action seems to be established. However, it was recently observed that at least at relatively low anorectic doses of amylin, the amylininduced c-Fos expression in the AP depended on the feeding status of rats. In other words, amylin produced a stronger c-Fos activation in rats that had been fasted prior to amylin administration than when fed ad libitum . The strong c-Fos response seen in fasted rats after low dose amylin was reproduced in rats fed a noncaloric diet (cellulose-based non-caloric mash; NCM). Therefore, 
Hypothalamic involvement in amylin action
Our previous studies suggested an involvement of the lateral hypothalamic area (LHA) in the anorectic action of amylin because the fasting induced neuronal activation in the LHA was specifically blocked by administration of an anorectic dose of amylin . Further, amylin reduced the expression of orexigenic neuropeptides in the LHA, i.e. orexin and melanin-concentrating hormone (MCH; Barth et al., 2003) . Interestingly, using double labeling immunohistochemistry we found that the neurons that are 
Interactions of amylin with CCK and PYY.
CCK and amylin interact in their control of eating. This may reflect a necessary part of CCK signaling because amylin antagonists attenuated CCK's anorectic action in rats (Lutz et al., 2000) , and the anorectic effect of CCK was almost completely abolished in the absence of endogenous amylin (Mollet et al., 2003a ). CCK's effect could be rescued by a small, subthreshold dose of amylin (Mollet et al., 2003a) . CCK signaling seems not to be required for amylin satiation because CCK antagonists had no effect on amylin-induced satiation (Morley et al., 1994 ).
While we have not yet tested combinations of amylin and PYY3-36 in feeding experiments, we recently found that the effect of amylin to induce c-Fos expression in the AP was markedly enhanced by a dose of PYY3-36 that by itself had no effect on AP neurons as gauged by c-Fos expression . This mechanism may be the neuronal correlate of the synergistic body weight lowering effect of amylin and PYY3-36 .
Interactions of amylin with leptin and insulin.
For several reasons, it seems plausible that amylin may interact with the adiposity signals leptin and insulin. First, amylin modulates CCK's effect on eating (Lutz et al., 2000; Mollet et al., 2003a) , and CCK's anorectic action has been shown repeatedly to be modulated by adiposity signals (e.g., Riedy et al., 1995; Morton et al, 2005) .
Further, Eiden and colleagues had shown that amylin's effect on eating is altered in animal models of defective leptin signaling. For example, leptin-deficient mice exhibited a markedly weaker anorectic response to the amylin agonist sCT than wildtype controls (Eiden et al., 2002) . Finally both amylin's and leptin's anorectic effects depend on histaminergic signaling via H1 receptors (Mollet et al., 2001 (Mollet et al., , 2003b ).
In fact, recent studies confirmed that leptin interacts with amylin to reduce food intake (Osto et al., 2007) . Leptin injected centrally reduced eating in rats more when co-administered with peripheral amylin than either peptide alone. This was true for effective doses of leptin but also for a subthreshold leptin dose. This is consistent with data showing that animals receiving a peripheral infusion of leptin plus amylin had a much larger decrease in body weight gain than rats receiving either hormone alone. Amylin restored responsiveness to leptin in diet-induced obesity (DIO) rats which are leptin resistant .
Similar to leptin, central insulin and peripheral amylin also interact to reduce food intake more than either peptide alone (Osto et al., 2007) . Consistent with this, subthreshold doses of peripheral insulin and amylin produced a significant anorectic effect when administered together (Rushing et al., 2000b) .
Collectively, these experiments demonstrate that central leptin and insulin may set the tone that determines amylin's anorectic potency.
Additional experiments suggested that a triple combination of amylin, leptin and PYY3-36 may further enhance the body weight lowering effect in rats.
Even though both leptin and ghrelin seem to affect food intake via the same neuronal network in the hypothalamic arcuate nucleus, ghrelin and amylin do not seem to interact for their effect on food intake (Osto et al., 2007) . This is consistent with recently published data by Kobelt and colleagues (Kobelt et al., 2006) . While ghrelin and CCK seem to interact (Kobelt et al., 2005) , no such interaction between ghrelin and amylin was reported (Kobelt et al., 2006) .
Further, the response to amylin was unaltered in rats with markedly reduced biologically active circulating ghrelin. These rats had received a series of vaccinations against endogenous ghrelin. The induced antibodies bound virtually all ghrelin in the circulation and prevented ghrelin from entering the brain . Collectively, these data indicate that ghrelin has no effect on the anorectic action of amylin.
Amylin as an adiposity signal.
The control of eating results in relatively stable energy stores as adipose tissue. After body weight loss, there is a tendency to eat more and to restore body weight. Analogously, after weight gain, there is a tendency to reduce food intake and lose the gained weight.
Adiposity signals are supposed to be implicated in this control sys-tem, and there is evidence to suggest that amylin may act as such a signal, similar to leptin and insulin.
In that respect, CCK and amylin clearly seem to differ from each other. On chronic administration, CCK as a "classical satiating signal", does not reduce body weight in rats because a sustained decrease in meal size is compensated by an increase in meal frequency (West et al., 1984) . Chronic administration of amylin, however, reduces eating by a decrease in meal size without a compensatory increase in meal frequency. In fact, some studies reported a reduction in meal frequency. Body weight is lowered by chronic amylin administration (Arnelo et al., 1998; Rushing et al., 2000a; Lutz et al., 2001a) .
Amylin provides information about the status of peripheral energy stores in the form of the adipose tissue mass because amylin is secreted in direct proportion to body fat mass (Pieber et al., 1994) .
Further, continuous peripheral infusion of amylin lowers body weight, and infusion of the amylin antagonist AC 187 has the opposite effect (Lutz et al., 2001a; Reidelberger et al., 2004) . Interesting-ly, chronic third ventricular (i3vt) infusion of amylin leads to considerable weight loss due to a reduced fat mass after 10 days, while that of amylin's antagonist AC 187 increases food intake and body fat mass without a concomitant increase in total body weight ). Finally, amylin deficient knock-out mice have increased body weight compared to controls. Hence, a sustained change in amylin signaling has profound effects on food intake, body weight, and body adiposity.
Recent unpublished studies from our laboratory are consistent with the idea that amylin signals body adiposity to the brain. In one experiment, based on a similar study with insulin by Chavez et al. (1995) , rats were chronically infused centrally with amylin or saline via a i3vt cannula. Half of the rats were fasted for two days to lower starting body weight. The important finding was that amylin-infused animals, independent of prior manipulations, achieved exactly the same body weight. This body weight was significantly lower than in saline-infused control animals. This is consistent with the idea that the central amylin level is a signal to the brain that indicates the available energy stores. Increased amylin levels as e.g. in obesity (Pieber et al., 1994) , would trigger an appropriate counterregulatory response. It is currently unknown to what extent an effect of amylin on energy expenditure (Wielinga et al., 2007b) contributes to this response.
A follow-up study revealed a very interesting phenomenon. This study suggests that animals may develop "resistance" to chronic or acute amylin action under certain conditions. Rats were overfed by offering a calorie-rich diet (Ensure R ) in addition to laboratory chow for 3 weeks. Control rats were fed chow ad libitum. After the overfeeding period, amylin or saline were delivered i3vt. Rats appeared to be unresponsive to amylin after overfeeding with the calorie-rich diet because only chow-fed animals showed a marked decrease in body weight gain when infused with amylin. Interestingly, exposure of rats to Ensure R for 3 days only also resulted in a decreased effect of acute central amylin on eating. The underlying physiological mechanisms are as yet unknown. Further, it is unknown how the observed phenomenon of amylin resistance may relate to previous reports that amylin reduces food intake less effectively in obese animals of some obesity models. It is however important to note that Eiden and colleagues (Eiden et al., 2002) had shown that higher doses of amylin are required to reduce eating in ob/ob mice, db/db mice and fa/fa rats. A similar phenomenon was observed in MC4Rko mice (Eiden et al., 2002) and in DIO rats. Collectively, these findings indicate that obese animals may respond less to a given dose of amylin. Because short-term exposure of rats to Ensure R also made rats less sensitive to amylin, a direct diet-related effect, independent of body weight, may also play a role.
Amylin's effect on energy metabolism
The amylin agonist sCT acutely increased energy expenditure in fasted rats. This was not related to altered physical activity or body temperature of the rats. Acute amylin administration had a similar effect but it was less pronounced than after sCT. This is most likely due to the shorter duration of action of amylin (Wielinga et al., 2007b ). Follow-up unpublished studies investigated the role of chronic amylin administration on energy expenditure. We showed that amylin prevented the decrease in energy expenditure that would normally be seen in animals that eat less (Wielinga et al., 2007a) .
Preliminary evidence suggests that amylin's effect on energy expenditure may also be mediated by the AP because low dose sCT infusion into the AP markedly increased energy expenditure.
Amylin and obesity therapy in humans
Several recent reports indicate that the amylin analogue pramlintide effectively reduces eating and body weight in humans (Hollander et al., 2004; Chapman et al., 2005) . Hence, it is considered an interesting treatment option for anti-obesity therapy. Type 2 diabetic overweight patients treated with a combination of insulin plus pramlintide required less insulin and had a better glycemic control than insulin treated controls. Patients treated with insulin plus pramlintide also lost body weight while insulin treated controls did not. Using the combination therapy, body weight was decreased most in severely obese patients with a body mass index >40 (Hollander et al., 2004) . Further, acute pramlintide treatment decreased the size of test meals by about 20% in both type 2 diabetics and nondiabetic obese individuals (Chapman et al., 2005) . Normal perceptions of fullness were undisturbed and side effects were minor. Pramlintide produced nausea in some but not all studies (Hollander et al., 2004; Chapman et al., 2005) , but this effect was usually transient (i.e., <4 weeks) and mild. Chapman et al. (2007) extended their studies and showed that acute pramlintide administration prior to a standardized pre-meal reduced ad libitum eating in healthy normal weight men during a subsequent buffet meal. Despite reduced caloric intake and reduced meal duration, similar hunger and fullness feelings were reported after the buffet meal. Another report produced consistent results in that 24-week pramlintide treatment of obese subjects resulted in reduced body weight due to a reduction in daily food intake and portion sizes (Smith et al., 2007) . Further, pramlintide also seemed to improve the perceived control of eating because less binge eating episodes were reported.
Based on promising rodent data that the coadministration of amylin and leptin produced stronger eating inhibitory effects than either hormone alone (Osto et al., 2007) , Roth et al. (2008a) recently published data on a 24-week study in overweight and obese individuals.
They convincingly showed that the coadministration of leptin plus amylin produced body weight loss that was significantly more pronounced than by either peptide alone. Parallel rodent experiments showed that amylin may restore leptin effectiveness in overweight individuals, possibly by upregulating the leptin-induced pSTAT3 expression in specific hypothalamic nuclei (Roth et al., 2008a) . The latter is consistent with our own unpublished data that acute amylin administration increased leptin receptor expression in the hypothalamus. Even though the underlying mechanisms seem largely unknown, it may be interesting to note that amylin may also produce additive anorectic and body weight lowering effects when combined with other anti-obesity drugs, e.g. sibutramine (Roth et al., 2008b) .
Overall, these data indicate that the amylin analogue pramlintide is a new promising anti-obesity therapy both for overweight type 2 diabetics and for overweight non-diabetics.
Summary, conclusions and future perspectives
Blood-borne amylin reduces meal size by stimulating neurons in the Future studies will concentrate on the brain's sensitivity to the anorectic and body weight lowering effects of amylin under various experimental conditions. This will follow up on findings that amylin sensitivity may be affected by specific dietary conditions. These studies will be conducted in the frame of ongoing efforts to elucidate the mechanisms of amylin action in the central nervous system.
Another focus will be on the usefulness of amylin for clinical thera- Table 1 Criteria for the physiological action of hormonal controls of eating (Geary, 2004) -
---------------------------------------------------------------------------------(1) Secretion
Secretion of the hormone is changed by eating. -
---------------------------------------------------------------------------------

